• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Detection in two hospitals of transferable ceftazidime-avibactam resistance in due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019.2019 年，希腊两家医院检测到一种新型 VEB 酶变体导致的可转移头孢他啶-阿维巴坦耐药，其具有 Lys234Arg 取代，该酶变体与β-内酰胺酶有关。
Euro Surveill. 2020 Jan;25(2). doi: 10.2807/1560-7917.ES.2020.25.2.1900766.
2
Outbreak of KPC-2-producing endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019.2019 年 9 月至 10 月，希腊爆发了产 KPC-2 的肺炎克雷伯菌，该菌对头孢他啶-阿维巴坦具有耐药性，是通过 VEB-1 突变体（VEB-25）介导的。
Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000028.
3
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
4
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.碳青霉烯酶 2（KPC-2），在 Ambler 位置 Asp179 的取代以及对头孢他啶-阿维巴坦的耐药性：β-内酰胺酶蛋白质工程产生独特的抗生素耐药表型。
mBio. 2017 Oct 31;8(5):e00528-17. doi: 10.1128/mBio.00528-17.
5
Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.产 KPC-2 肺炎克雷伯菌中由超广谱β-内酰胺酶 VEB-25 引起的对头孢他啶-阿维巴坦的耐药性。
Eur J Clin Microbiol Infect Dis. 2023 May;42(5):639-644. doi: 10.1007/s10096-023-04582-0. Epub 2023 Mar 6.
6
Evolution of Under the Pressure of Carbapenems and Ceftazidime/Avibactam in a Patient With Persistent Bacteremia Caused by .碳青霉烯类和头孢他啶/阿维巴坦压力下导致持续菌血症的 患者的演变。
J Korean Med Sci. 2024 Jul 1;39(25):e208. doi: 10.3346/jkms.2024.39.e208.
7
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
8
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
9
A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring Isolated in New York City.一株耐头孢他啶-阿维巴坦、碳青霉烯类敏感的肺炎克雷伯菌的分离与鉴定：来自纽约市的报告。
mSphere. 2020 Aug 26;5(4):e00775-20. doi: 10.1128/mSphere.00775-20.
10
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.

引用本文的文献

1
Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.突破耐药性：新型β-内酰胺酶抑制剂（阿维巴坦、瓦博巴坦、瑞来巴坦）抗多重耐药超级细菌的比较综述
Antibiotics (Basel). 2025 May 21;14(5):528. doi: 10.3390/antibiotics14050528.
2
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic strains.头孢吡肟-他尼硼巴坦对工程化同基因菌株中定义的190种β-内酰胺酶的覆盖谱。
Antimicrob Agents Chemother. 2025 May 7;69(5):e0169924. doi: 10.1128/aac.01699-24. Epub 2025 Apr 1.
3
Outbreak of High-Risk Clone ST323 Resistant to Ceftazidime-Avibactam Due to Acquisition of and to Cefiderocol Due to Mutated Gene.因获得blaOXA-181基因而对头孢他啶-阿维巴坦耐药且因mcr-1基因变异而对头孢地尔耐药的高危克隆ST323暴发。
Antibiotics (Basel). 2025 Feb 21;14(3):223. doi: 10.3390/antibiotics14030223.
4
Molecular characteristics and evaluation of the phenotypic detection of carbapenemases among and via whole genome sequencing.通过全基因组测序对 和 中的碳青霉烯酶的分子特征和表型检测进行评估。
Front Cell Infect Microbiol. 2024 Jul 4;14:1357289. doi: 10.3389/fcimb.2024.1357289. eCollection 2024.
5
Rapid Detection of Ceftazidime/Avibactam Susceptibility/Resistance in Enterobacterales by Rapid CAZ/AVI NP Test.快速 CAZ/AVI NP 试验检测肠杆菌科中头孢他啶/阿维巴坦的药敏/耐药性。
Emerg Infect Dis. 2024 Feb;30(2):255-261. doi: 10.3201/eid3002.221398.
6
Three lineages causing bloodstream infections variably dominated within a Greek hospital over a 15 year period.在过去的 15 年中，希腊一家医院的血流感染患者中，三种不同的菌属存在不同程度的主导地位。
Microb Genom. 2023 Aug;9(8). doi: 10.1099/mgen.0.001082.
7
Neonatal Bloodstream Infection with Ceftazidime-Avibactam-Resistant -Producing Carrying .携带产头孢他啶-阿维巴坦耐药菌的新生儿血流感染
Antibiotics (Basel). 2023 Aug 5;12(8):1290. doi: 10.3390/antibiotics12081290.
8
Genetic Characterization of Carbapenem-Resistant Clinical Isolates in a Tertiary Hospital in Greece, 2018-2022.2018 - 2022年希腊一家三级医院耐碳青霉烯临床分离株的基因特征分析
Antibiotics (Basel). 2023 May 28;12(6):976. doi: 10.3390/antibiotics12060976.
9
Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.产 KPC-2 肺炎克雷伯菌中由超广谱β-内酰胺酶 VEB-25 引起的对头孢他啶-阿维巴坦的耐药性。
Eur J Clin Microbiol Infect Dis. 2023 May;42(5):639-644. doi: 10.1007/s10096-023-04582-0. Epub 2023 Mar 6.
10
Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients.重症患者中由难治疗和泛耐药革兰氏阴性菌引起的感染的当前及潜在治疗选择
Antibiotics (Basel). 2022 Jul 26;11(8):1009. doi: 10.3390/antibiotics11081009.

本文引用的文献

1
In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17).在 INFORM 全球监测项目（2015-17 年）期间收集的耐碳青霉烯类肠杆菌科细菌的体外头孢他啶/阿维巴坦活性。
J Antimicrob Chemother. 2020 Feb 1;75(2):384-391. doi: 10.1093/jac/dkz456.
2
Emergence of ceftazidime-avibactam-resistant during treatment, Finland, December 2018.2018 年 12 月，芬兰在治疗期间出现对头孢他啶-阿维巴坦耐药的 。
Euro Surveill. 2019 May;24(19). doi: 10.2807/1560-7917.ES.2019.24.19.1900256.
3
In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.产 KPC 肺炎克雷伯菌在头孢他啶/阿维巴坦治疗期间耐药亚群的体内进化。
J Antimicrob Chemother. 2018 Jun 1;73(6):1525-1529. doi: 10.1093/jac/dky082.
4
Mutations in That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases.赋予头孢他啶-阿维巴坦耐药性的突变编码新型KPC-3变体，其作为超广谱β-内酰胺酶发挥作用。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02534-16. Print 2017 May.
5
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
6
Circulation of a multiresistant, conjugative, IncA/C plasmid within the nosocomial Providencia stuartii population in the Athens area.一种多重耐药、可接合、IncA/C质粒在雅典地区医院环境中普罗威登斯菌群体内的传播情况。
Diagn Microbiol Infect Dis. 2015 May;82(1):62-4. doi: 10.1016/j.diagmicrobio.2015.02.009. Epub 2015 Feb 23.
7
Avibactam and inhibitor-resistant SHV β-lactamases.阿维巴坦与耐抑制剂的SHVβ-内酰胺酶
Antimicrob Agents Chemother. 2015 Jul;59(7):3700-9. doi: 10.1128/AAC.04405-14. Epub 2015 Feb 17.
8
Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.对阿维巴坦抑制作用具有抗性的β-内酰胺酶KPC-2变体。
Antimicrob Agents Chemother. 2015 Jul;59(7):3710-7. doi: 10.1128/AAC.04406-14. Epub 2015 Feb 9.
9
Diversity of acquired β-lactamases amongst Klebsiella pneumoniae in Greek hospitals.希腊医院中肺炎克雷伯菌获得性β-内酰胺酶的多样性。
Int J Antimicrob Agents. 2012 Feb;39(2):178-80. doi: 10.1016/j.ijantimicag.2011.09.024. Epub 2011 Nov 21.
10
Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.对临床分离的大肠杆菌菌株产生的新型耐抑制剂β-内酰胺酶SHV-84的生化研究。
Antimicrob Agents Chemother. 2010 May;54(5):2271-2. doi: 10.1128/AAC.01442-09. Epub 2010 Mar 8.

2019 年，希腊两家医院检测到一种新型 VEB 酶变体导致的可转移头孢他啶-阿维巴坦耐药，其具有 Lys234Arg 取代，该酶变体与β-内酰胺酶有关。

Detection in two hospitals of transferable ceftazidime-avibactam resistance in due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019.

机构信息

Laboratory of Bacteriology, Hellenic Pasteur Institute, Athens, Greece.

Department of Clinical Microbiology, Thriassio General Hospital, Elefsina, Greece.

出版信息

Euro Surveill. 2020 Jan;25(2). doi: 10.2807/1560-7917.ES.2020.25.2.1900766.

DOI:10.2807/1560-7917.ES.2020.25.2.1900766
PMID:31964461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6976883/
Abstract

Two ceftazidime-avibactam (CAZ-AVI)-resistant carbapenemase (KPC)-positive strains, including one pandrug resistant, were isolated in 2019 from two Greek hospitals. The strains were sequence types (ST)s 258 and 147 and both harboured similar self-transmissible IncA/C2 plasmids encoding a novel Lys234Arg variant of the Vietnamese extended-spectrum β-lactamase (VEB)-1, not inhibited by AVI (VEB-25). Conjugal transfer of VEB-25-encoding plasmids to yielded CAZ-AVI-resistant clones, supporting that VEB-25 is directly linked to the derived phenotype.

摘要

2019 年，从希腊的两家医院中分离出两株耐头孢他啶-阿维巴坦（CAZ-AVI）的碳青霉烯酶（KPC）阳性菌株，其中一株为泛耐药菌株。这两株菌的序列类型（ST）分别为 258 和 147，均携带相似的可自我传播的 IncA/C2 质粒，可编码一种新型越南超广谱β-内酰胺酶（VEB）-1 的 Lys234Arg 变异体，该变异体不受 AVI（VEB-25）抑制。VEB-25 编码质粒向 的接合转移产生了对 CAZ-AVI 耐药的克隆，这表明 VEB-25 与衍生的表型直接相关。